fda removes tirzepatide from shortage list As of February 21, 2025, the updated its drug list, marking the semaglutide injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A is tirzepatide on the fda

Symptoms include shakiness, sweating, confusion, rapid heartbeat, and extreme hunger

GLP-1 is also a central regulator of hunger and reward pathways in the brain, which is where its role in addiction is starting to become clearer

HIMS had been getting away with selling compounded injectable semaglutide in a post-shortage regulatory environment for over a year, largely uncontested

Multimodal pathway analysis benchmarking We evaluated the performance of SpaMTPs pathway enrichment analysis against existing tools for bulk data (MetaboAnalyst and Ingenuity Pathway Analysis (IPA)) 31,32

If, for any reason, there are challenges with insurance coverage, there are other alternative payment options and assistance programs that you can explore to make Semaglutide GLP-1 injections more affordable